Progression and clinical application of tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia

VernacularTitle:酪氨酸激酶抑制剂治疗慢性髓性白血病进展及临床应用
Author: Jiawen CHEN ; Tao WU ; Hai BAI
Keywords: Protein-tyrosine kinases/AI/TU; Leukemia,myelogenous,chronic,BCR-ABL positive/DT; Review
From: Journal of Chinese Physician 2017;19(4):625-629
CountryChina
Language:Chinese
Abstract: Chronic myelogenous leukemia (CML) has a high proportion in hematologic malignancy.Past decade,the appearance and development of tyrosine kinase inhibitors (TKIs) is the milestone of the treatment of CML.TKIs have antitumor effect with inhibition of the phosphorylation of kinases and the downstream signal transduction.In recent years,many large medical institutions at home and abroad worked on clinical experiment researches to investigate the mechanism of TKIs and how to choose TKIs in CML patients.This work is of great significance to the clinic.